Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

SIMPLE SUMMARY: Although it is known that anti-PD1/L1 monotherapy does not render significant benefit in patients with EGFR-mutant lung adenocarcinoma, whether the addition of anti-PD1/L1 therapy to chemotherapy can enhance chemotherapy efficacy for TKI-refractory EGFR-mutant lung adenocarcinoma pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Lingzhi, Lewis, Whitney E., Nilsson, Monique, Patel, Sonia, Varghese, Susan, Rivera, Melvin J., Du, Robyn R., Chen, Pingjun, Kemp, Haley N., Rinsurongkawong, Waree, Heeke, Simon, Spelman, Amy R., Elamin, Yasir Y., Negrao, Marcelo V., Sepesi, Boris, Gibbons, Don L., Lee, J. Jack, Wu, Jia, Vokes, Natalie I., Heymach, John V., Zhang, Jianjun, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323840/
https://www.ncbi.nlm.nih.gov/pubmed/35884533
http://dx.doi.org/10.3390/cancers14143473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323840/
https://www.ncbi.nlm.nih.gov/pubmed/35884533
http://dx.doi.org/10.3390/cancers14143473

Ejemplares similares